Lynparza® improves invasive disease-free survival in breast cancer trial europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Women with hereditary breast cancer, triggered by the BRCA1 or BRCA2 genes, stand a better chance of survival following successful trials of a drug that cuts the likelihood of the cancer returning after treatment. A major trial carried out by academic researchers to see whether olaparib can prevent recurrence was stopped early – after two-and-a-half years instead of the planned 10 years – when the benefits of the drug became clear. The results,.
email article
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival (DFS) in patients with early, high-risk HER2-negative breast cancer and germline
BRCA mutations, according to results from a phase III study.
Interim findings from the OlympiA trial showed that patients receiving the PARP inhibitor had a 42% reduction in the risk of invasive DFS versus patients receiving placebo (HR 0.58, 95% CI 0.41-0.82), and a 43% reduction in the risk of distant DFS (HR 0.57, 95% CI 0.39-0.83), reported Andrew Tutt, MB, ChB, PhD, of the Institute of Cancer Research and Kings College in London. The OlympiA study is the first study to report the benefits of a PARP inhibitor, olaparib, as an adjuvant treatment for early forms of germline